One of the best overviews of emerging mCRPC treatments to date by @PBarataMD . Bispecifics and ADCs are the future, alongside advances in radioligands. Despite all we have achieved in past 10 years, still a clear unmet need for mCRPC post docetaxel and ARPI, where rwOS ~12 mths

Excellent discussion by @scocmem looking forward to discussing more details @Uromigos meeting Nashville Nov 7-8! @tompowles1 @brian_rini @shilpaonc @montypal @neerajaiims @OncoAlert @MichvdHeijden @DrRanaMcKay @crisuarez08 @DrRosenbergMSK @alantanmd @AmandaNizamMD @Dr_Aggen

Randomized trials testing ctDNA and HER-2 biomarkers in bladder cancer both delivered positive results with OS #ESMO25 . Here @scocmem described how these and other biomarkers are changing bladder cancer. @PGrivasMDPhD @OncoAlert #uromigosLive

#UromigosLive 2025がいよいよ11月7日、8日で開催されます。今年も #UromigosCup 参加に向けてΤシャツを作りました🤭 3人で頑張ってきます‼️ @YujiMiura5 @hiroshi_dko @Uromigos

I suspect an ADC, alone or in combination with a T cell engager, will beat docetaxel chemo in prostate cancer in thr not too distant future #uromigosLive . Here @PBarataMD tells us how and when that might happen. @Silke_Gillessen @OncoAlert @Annals_Oncology @APCCC_Lugano

Some things just work, even if you feel as though they should not.

First ph3 RCT showing PFS benefit with adjuvant combination therapy in RCC! Growing evidence to support periop therapy following host of negative studies. Work to be done in identifying those most likely to benefit from therapy

Treatment after EVP in bladder cancer is undefined. Izalontamab brenitecan (HER2/3 TROP2 ADC) has good activity in bladder+lung cancer. A global randomised phase III has started enrolment 👉 Iza Bren alone vs platinum chemo in previously treated pts (including EVP). @OncoAlert

We are excited to open this much needed trial with a dual-targeted ADC led by @shilpaonc at @ClevelandClinic soon! @ChrisWeeMD @MosheOrnsteinMD @DemitriDedousis @LauraBukavinaMD @BladderCancerUS

The Eurasia team 🇯🇵 🇨🇳 🇦🇺 🇳🇱 🇪🇸 🇮🇳 are now 7-0 ahead for the Uromigos cup 🏆 @MichvdHeijden getting a record 98 ♥️. The final round for Eurasia is @crisuarez08 🇪🇸 🇪🇸 🇪🇸 🇪🇸 with a little help from Gaudi. It feels hard to beat. The #UromigosLive!meeting is next week @OncoAlert

Full arm + hand tracking in Eidon SYM, our full stack robotics system. We are building a complete stack connecting the triangle of our - cost effective + accurate robotics data collection hardwares - simulation environment - robot hardware. The flow must be completed.

Team America 🇺🇸 🇨🇦 have their final entry for Uromigos cup 🏆. Eurasia is winning. Here @TDorffOnc goes for a 🇺🇸 🇦🇺 fusion photo with kangaroos. ♥️ =points. Surely it’s time for a win for the Americas. #UromigosLive meeting is next week btw 7th/8th @OncoAlert @montypal

🚨Big day for RCC: 2 positive belzutifan combo studies‼️ - Belzutifan + pembro (adjuvant): DFS ✅ - Belzutifan + lenvatinib (pretreated mx): PFS ✅ Well tolerated & promising partner but is combining better than sequencing? Will EMA need OS? @OncoAlert @OncoReporte @DrChoueiri

@Uromigos @crisuarez08 @OncoAlert Wow, this is for sure the best picture in the series! Captain @crisuarez08 saved the best for last!! Vote ❤️for team Eurasia uromigos 🏆 @LAUrology_NL @KoenvdMijn @Brouwer_MD_PhD @MyriamChalabi @y_loriot @AlbigesL So looking fwd to #UromigosLive! meeting

2️⃣ positive trials for belzutifan on the same day! LITESPARK-022 tests adjuvant belzutifan+pembro vs pembro alone post surgery in ccRCC. It is +ve for DFS. It’s the 1st +ve combination trial in adjuvant RCC & moves pateint care forward.@DrChoueiri https://t.co/8s5MvBU2NQ

The hardest part about getting in shape: It's not the workout. It's the 23 hours when you're not working out. The decisions at restaurants. The snacks at midnight. The excuses at 5am. The gym is easy. Life is hard. Fitness isn't about what you do for an hour. It's about what you

LITESPARK-011 (lenvatinib + belzutifan vs cabozantinib in pretreated clear cell RCC) is positive for PFS. Belzutifan is well tolerated making it a good partner. It’s the 1st positive targeted therapy combo RIII trial in RCC @OncoAlert #UromigosLive https://t.co/E3i1VH6hvy

🎥 #UromigosShorts vídeos sobre distintos temas de Oncología GU. Los vídeos con ➕visualizaciones recibirán un premio durante #UromigosLive 👇🏼En este vídeo, la Dra. Sara Coca Membribes comenta sobre "Biomarcadores en cáncer urotelial". @OncoAlert @Uromigos @uromigosjapan

Radioisotopes in prostate cancer are expanding quickly. @anis_a_hamid describes novel targets such as potential (STEAP2, hK2) as well as novel combination (IO, chemo, PARPi). Optimal dosing is uncertain & also addressed as well as new isotopes such as actinium or lead @OncoAlert

This is one of my favourite Uromigos short videos. @anis_a_hamid describes the next steps for radioisotopes in prostate cancer. A number of new studies with novel agents and alternative approaches are starting.

Excited for Izabright for patients s/p EV+P. The first of many 2nd gen ADCs with dual antigen targets.

Are you incorporating MDT for oligometastatic prostate cancer❓ ✅Here's a brief recap of key trials for #UromigosLive, including ongoing RCT's: METANOVA, TERPS, PROMETHEAN, and KNIGHTS. Please share and comment! #ProstateCancer

🎶 Wondering how to tackle variant histologies in bladder cancer? Think of them as music genres—same stage, different openers (neoadj.) and headliners (1st line tx). 🎤 From micropapillary to plasmacytoid—each has a style & strategy. 🎧 Watch here ⬇️ @Uromigos @Dr_Aggen